Annals of Oncology Advance Access originally published online on May 4, 2006
Annals of Oncology 2006 17(7):1065-1071; doi:10.1093/annonc/mdl047
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2006 European Society for Medical Oncology
Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer
1 European Institute of Oncology, Milan, Italy; 2 Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy; 3 E.O. Ospedali Galliera, Genoa, Italy; 4 Fondazione S. Maugeri, Pavia, Italy; 5 Institute of Medical Statistics and Biometry, University of Milan, Italy; 6 Department of Pharmacology, Dartmouth Medical School, Hanover, NH, USA
* Correspondence to: Prof. U. Veronesi, Scientific Director, European Institute of Oncology, Via G. Ripamonti, 435 – 20141 Milan, Italy. Tel: +39 02 57489221; Fax: +39 02 57489210; E-mail: umberto.veronesi{at}ieo.it
Purpose: The synthetic retinoid fenretinide administered for 5 years for prevention of second breast cancer showed no difference after a median of 8 years, but a possible reduction in premenopausal women. We conducted a long-term analysis in a subgroup of women who were regularly followed up in a single center.
Patients and methods: We analyzed data after a median follow-up of 14.6 years (IQ range, 12.3–16.3 years) from 1739 women aged 30–70 (872 in the fenretinide arm and 867 in the observation arm), representing 60% of the initial cohort of 2867 women. The main efficacy endpoint was second primary breast cancer (contralateral or ipsilateral).
Results: The number of second breast cancers was 168 in the fenretinide arm and 190 in the control arm (hazard ratio = 0.83, 95% CI, 0.67–1.03). There were 83 events in the fenretinide arm and 126 in the observation arm in premenopausal women (HR = 0.62, 95% CI, 0.46–0.83), and 85 and 64 events in postmenopausal women (HR = 1.23, 95% CI, 0.63–2.40). The younger were the women, the greater was the risk reduction associated with fenretinide, which attained 50% in women aged 40 years or younger and disappeared after age 55 (P-age*treatment interaction = 0.023). There was no difference in cancers in other organs, distant metastases or survival.
Conclusions: Fenretinide induces a significant risk reduction of second breast cancer in premenopausal women, which is remarkable at younger ages, and persists several years after treatment cessation. Since adverse events are limited, a trial in young women at high-risk is warranted.
Key words: breast neoplasms, chemoprevention, fenretinide, clinical trial
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Decensi, C. Robertson, A. Guerrieri-Gonzaga, D. Serrano, M. Cazzaniga, S. Mora, M. Gulisano, H. Johansson, V. Galimberti, E. Cassano, et al. Randomized Double-Blind 2 x 2 Trial of Low-Dose Tamoxifen and Fenretinide for Breast Cancer Prevention in High-Risk Premenopausal Women J. Clin. Oncol., August 10, 2009; 27(23): 3749 - 3756. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Visvanathan, R. T. Chlebowski, P. Hurley, N. F. Col, M. Ropka, D. Collyar, M. Morrow, C. Runowicz, K. I. Pritchard, K. Hagerty, et al. American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction J. Clin. Oncol., July 1, 2009; 27(19): 3235 - 3258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Appierto, P. Tiberio, M. G. Villani, E. Cavadini, and F. Formelli PLAB induction in fenretinide-induced apoptosis of ovarian cancer cells occurs via a ROS-dependent mechanism involving ER stress and JNK activation Carcinogenesis, May 1, 2009; 30(5): 824 - 831. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Rock, L. Natarajan, M. Pu, C. A. Thomson, S. W. Flatt, B. J. Caan, E. B. Gold, W. K. Al-Delaimy, V. A. Newman, R. A. Hajek, et al. Longitudinal Biological Exposure to Carotenoids Is Associated with Breast Cancer-Free Survival in the Women's Healthy Eating and Living Study Cancer Epidemiol. Biomarkers Prev., February 1, 2009; 18(2): 486 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Formelli, E. Meneghini, E. Cavadini, T. Camerini, M. G. Di Mauro, G. De Palo, U. Veronesi, F. Berrino, and A. Micheli Plasma Retinol and Prognosis of Postmenopausal Breast Cancer Patients Cancer Epidemiol. Biomarkers Prev., January 1, 2009; 18(1): 42 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Johansson, S. Gandini, A. Guerrieri-Gonzaga, S. Iodice, M. Ruscica, B. Bonanni, M. Gulisano, P. Magni, F. Formelli, and A. Decensi Effect of Fenretinide and Low-Dose Tamoxifen on Insulin Sensitivity in Premenopausal Women at High Risk for Breast Cancer Cancer Res., November 15, 2008; 68(22): 9512 - 9518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Villablanca, D. Zhou, B. Valentinis, A. Negro, L. Raccosta, L. Mauri, A. Prinetti, S. Sonnino, C. Bordignon, C. Traversari, et al. Selected natural and synthetic retinoids impair CCR7- and CXCR4-dependent cell migration in vitro and in vivo J. Leukoc. Biol., September 1, 2008; 84(3): 871 - 879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. T. Pruett, A. Bushnev, K. Hagedorn, M. Adiga, C. A. Haynes, M. C. Sullards, D. C. Liotta, and A. H. Merrill Jr. Thematic Review Series: Sphingolipids. Biodiversity of sphingoid bases ("sphingosines") and related amino alcohols J. Lipid Res., August 1, 2008; 49(8): 1621 - 1639. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kadara, E. Tahara, H.-J. Kim, D. Lotan, J. Myers, and R. Lotan Involvement of Rac in Fenretinide-Induced Apoptosis Cancer Res., June 1, 2008; 68(11): 4416 - 4423. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. R. Howe Rexinoids and Breast Cancer Prevention Clin. Cancer Res., October 15, 2007; 13(20): 5983 - 5987. [Full Text] [PDF]
|
|
|
|
|
|
A. Albini, D. M. Noonan, and N. Ferrari Molecular Pathways for Cancer Angioprevention Clin. Cancer Res., August 1, 2007; 13(15): 4320 - 4325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Anding, J. S. Chapman, D. W. Barnett, R. W. Curley Jr., and M. Clagett-Dame The Unhydrolyzable Fenretinide Analogue 4-Hydroxybenzylretinone Induces the Proapoptotic Genes GADD153 (CHOP) and Bcl-2-Binding Component 3 (PUMA) and Apoptosis that Is Caspase- Dependent and Independent of the Retinoic Acid Receptor Cancer Res., July 1, 2007; 67(13): 6270 - 6277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Micheli, E. Meneghini, G. Secreto, F. Berrino, E. Venturelli, A. Cavalleri, T. Camerini, M. G. Di Mauro, E. Cavadini, G. De Palo, et al. Plasma Testosterone and Prognosis of Postmenopausal Breast Cancer Patients J. Clin. Oncol., July 1, 2007; 25(19): 2685 - 2690. [Abstract] [Full Text] [PDF]
|
|